Using CDK6 inhibitor, palbociclib could effectively suppress tumorigenic properties in TMZ-R cells and decrease TMZ-R’s ability to generate M2 GAM and glioma stem cells, in association with down-regulation of lncSNHG15 and up-regulation of tumor suppressor miR-627. This evidence concerns the gene CDK6 and central nervous system cancer.